Somru Bioscience specializes in the development of advanced biotechnological solutions, particularly in the realm of drug development and biosimilars. The company offers a range of Immunogenicity and Pharmacokinetic ELISA kits designed for the precise detection of anti-drug antibodies and the accurate measurement of biologics in biological matrices. Their innovative intelli.b™ platform facilitates comparability testing of biologics and biosimilars at a molecular level, aligning with FDA guidance for fingerprint-like analysis. This comprehensive approach aims to streamline the drug development process, reducing both time and costs for biotechnology and biopharmaceutical companies.

In addition to their ELISA kits, Somru is pioneering a unique chicken monoclonal antibody technology that leverages the immune response of chickens to produce antibodies with superior specificity and stability compared to traditional mammalian models. This technology allows for a broader epitope recognition due to the phylogenetic differences between chickens and humans, resulting in a more robust immune response. Furthermore, chicken antibodies avoid common interferences associated with mammalian antibodies, enhancing the accuracy of immunoassays. Somru's commitment to innovation in antibody development positions them as a key player in the biotechnology sector, particularly in the context of personalized medicine and biosimilar development.

Canada

Somru BioScience is an emerging biotechnology company dedicated to developing breakthrough antibody technology for research, diagnostic and therapeutic applications.

Somru Bioscience

Company Details